

David H Fitchett

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3023797/david-h-fitchett-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93
papers

13,396
citations

34
h-index

102
g-index

102
ext. papers

16,762
ext. citations

7.5
avg, IF

6.41
L-index

#	Paper	IF	Citations
93	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.. <i>Diabetes Research and Clinical Practice</i> , 2022 , 109837	7.4	1
92	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021 ,	3.7	5
91	Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1085-1093	12.3	9
90	Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021 , 8, 2603-2607	3.7	4
89	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 568-577	7.9	1
88	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021 , 27, 888-895	3.3	4
87	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2775-2784	6.7	2
86	Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>American Journal of Hypertension</i> , 2020 , 33, 1092-1101	2.3	9
85	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 418-435	18.1	59
84	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	8
83	Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1151-1156	6.7	6
82	Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1207-1214	6.7	14
81	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020 , 2, 402-415	2	0
80	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1141-1150	6.7	9
79	131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. <i>Diabetes</i> , 2020 , 69, 131-LB	0.9	1
78	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 126-135	12.3	30
77	Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 631-639	6.7	39

76	Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME. <i>ESC Heart Failure</i> , 2020 , 7, 3401	3.7	9
75	Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 200	8.7	5
74	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 949-959	18.1	14
73	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , 2020 , 38, 1829-1840	1.9	10
72	Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME. <i>Diabetes and Vascular Disease Research</i> , 2020 , 17, 1479164120975256	3.3	4
71	Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME \square trial. <i>European Heart Journal</i> , 2020 , 41, 209-217	9.5	20
70	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Circulation</i> , 2019 , 140, 1693-1702	16.7	205
69	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME \square trial. <i>Age and Ageing</i> , 2019 , 48, 859-866	3	34
68	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019 , 42, e42-e44	14.6	16
67	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2019 , 12, e005875	7.6	30
66	A safety update on sodium glucose co-transporter 2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21 Suppl 2, 34-42	6.7	40
65	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019 , 139, 1458-1460	16.7	34
64	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. <i>European Journal of Heart Failure</i> , 2019 , 21, 386-388	12.3	21
63	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , 2019 , 139, 1384-1395	16.7	115
62	Management of Acute Coronary Syndromes. <i>Canadian Journal of Diabetes</i> , 2018 , 42 Suppl 1, S190-S195	2.1	4
61	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>Canadian Journal of Cardiology</i> , 2018 , 34, 736-743	3.8	5
60	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME \square trial. <i>European Heart Journal</i> , 2018 , 39, 363-370	9.5	171
59	Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 364-367	15.1	28

58	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 214-233	3.8	125
57	Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME ² . <i>Diabetologia</i> , 2018 , 61, 1522-1527	10.3	33
56	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018 , 137, 119-129	16.7	252
55	Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME ² trial. <i>Diabetologia</i> , 2018 , 61, 2155-2163	10.3	100
54	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1350-1361	3.8	2
53	Diabetes Mellitus and Cardiovascular Disease: An Evidence-Based Review of Provincial Formulary Coverage. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1362-1364	3.8	0
52	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. <i>JACC: Heart Failure</i> , 2018 , 6, 813-822	7.9	20
51	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018 , 41, 356-363	14.6	365
50	Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. <i>Circulation</i> , 2018 , 137, 405-407	16.7	96
49	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018 , 138, 1599-1601	16.7	16
48	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. <i>Circulation</i> , 2018 , 138, 1904-1907	16.7	75
47	Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice. <i>European Endocrinology</i> , 2018 , 14, 40-49	3.4	9
46	Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME ² randomised trial. <i>Diabetologia</i> , 2018 , 61, 1712-1723	10.3	58
45	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 940-942	3.8	4
44	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017 , 48, 1218-1225	6.7	86
43	SGLT2 inhibitors in the real world: too good to be true?. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 673-675	18.1	9
42	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. <i>European Journal of Heart Failure</i> , 2017 , 19, 43-53	12.3	76
41	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 366-377	3.8	19

40	Optimizing the Prevention of Cardiovascular Events. <i>Canadian Journal of Cardiology</i> , 2016 , 32, S13-4	3.8	
39	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 323-34	59.2	1956
38	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , 2016 , 32, S35-65	3.8	138
37	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1221.e11-1221.e18	3.8	5
36	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016 , 32, S15-34	3.8	7
35	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. <i>Circulation</i> , 2016 , 134, 752-72	16.7	631
34	Efficacy and safety of a routine early invasive strategy in relation to time from symptom onset to fibrinolysis (a subgroup analysis of TRANSFER-AMI). <i>American Journal of Cardiology</i> , 2015 , 115, 1005-12	3	3
33	Cardiology patient page. Statin intolerance. <i>Circulation</i> , 2015 , 131, e389-91	16.7	41
32	SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 90-100	3.3	283
31	The metabolic syndrome is an important concept in therapeutic decision-making. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 596-600	3.8	7
30	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015 , 373, 2117-28	59.2	6064
29	Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies. <i>Canadian Journal of Diabetes</i> , 2015 , 39 Suppl 5, S176-82	2.1	0
28	Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1725-31	3.8	20
27	Comparison of the efficacy of pharmacoinvasive management for ST-segment elevation myocardial infarction in smokers versus non-smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction). <i>American Journal of Cardiology</i> , 2014 , 114, 955-61	3	9
26	Cardiology Patient Page: coronary artery revascularization in patients with diabetes mellitus. <i>Circulation</i> , 2014 , 130, e104-6	16.7	6
25	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). <i>Cardiovascular Diabetology</i> , 2014 , 13, 102	8.7	153
24	Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation: the clinical dilemma of triple therapy. <i>Current Opinion in Cardiology</i> , 2014 , 29, 1-9	2.1	6
23	Risk stratification and selection for statin therapy: going beyond Framingham. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 667-70	3.8	6

22	Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1042-7	3.8	18
21	Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 317-28	18.1	140
20	Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 960-8	3.8	15
19	Potential role of rivaroxaban in patients with acute coronary syndrome. <i>Drug Design, Development and Therapy</i> , 2012 , 6, 349-57	4.4	3
18	Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. <i>Canadian Journal of Cardiology</i> , 2011 , 27, e1-e33	3.8	116
17	Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction. <i>Canadian Journal of Cardiology</i> , 2011 , 27 Suppl A, S402-12	3.8	31
16	Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS. <i>Canadian Journal of Cardiology</i> , 2011 , 27 Suppl A, S387-401	3.8	24
15	Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010 , 3, 530-7	5.8	52
14	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 683-9	3.8	63
13	Results of the ONTARGET and TRANSCEND studies: an update and discussion. <i>Vascular Health and Risk Management</i> , 2009 , 5, 21-9	4.4	15
12	Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy. <i>American Journal of Cardiology</i> , 2008 , 102, 1142-5	3	22
11	Tailored antithrombotic therapy for acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2008 , 6, 935-44	2.5	
10	Use of cardiac catheterization for non-ST-segment elevation acute coronary syndromes according to initial risk: reasons why physicians choose not to refer their patients. <i>Archives of Internal Medicine</i> , 2008 , 168, 291-6		53
9	Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. <i>European Heart Journal</i> , 2007 , 28, 1072-8	9.5	197
8	Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. <i>Archives of Internal Medicine</i> , 2007 , 167, 1009-16		118
7	Clinical trial update: focus on the ONTARGET study. <i>Vascular Health and Risk Management</i> , 2007 , 3, 901-8	4.4	3
6	Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 663-77	3.8	9
5	Age-related differences in the management and outcome of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006 , 151, 352-9	4.9	79

4	Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. <i>American Heart Journal</i> , 2006, 152, 676-83	4.9	28
3	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006, 152, 676-83	4.9	37
2	In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. <i>American Journal of Cardiology</i> , 2005, 96, 913-6	3	95
1	Enoxaparin and percutaneous coronary intervention: a Canadian perspective. <i>Canadian Journal of Cardiology</i> , 2005, 21, 501-7	3.8	1